On June 15, HTDK was invited to participate in the 6th Future Healthcare Top 100 Conference, where Andy Tian, General Manager of HTDK’s Business Channel Management Division, delivered a keynote speech titled “Capital Influx, Hot Market: How to Accelerate the Commercialization of Ophthalmic Products.” In his speech, Tian joined experts and scholars in the ophthalmology field to discuss the development trends of the industry, driven by capital and innovative technologies, and shared HTDK’s exemplary practices in accelerating the growth of the eye health industry.

The Future Healthcare Top 100 Conference is a premier annual event in China, focusing on healthcare industry trends. Since its inception in 2016, the conference has been successfully held five times, attracting nearly 20,000 participants from the industry. It has become the largest and most influential event integrating industry and capital in China’s healthcare innovation sector.

As a leader in the commercialization of ophthalmic services, HTDK has spent 16 years providing end-to-end commercialization solutions for high-value medical device products. With extensive experience serving top multinational clients in ophthalmology, HTDK continues to lead and drive innovative commercialization processes. The invitation to participate in this conference allowed HTDK to engage with industry experts, gain valuable insights, and explore the future of ophthalmology and technological innovation.

During the forum, Andy Tian analyzed the development trends of the ophthalmology industry from four perspectives: policy, economics, society, and technological innovation. He noted that eye health has become a crucial aspect of the “Healthy China” initiative, and healthcare reforms are further promoting the ophthalmic medical industry. China’s ophthalmology market is witnessing a “small field, big growth” trend. Policies like the Regulations on the Administration of Medical Institutions encourage the development of various forms of medical institutions, including private ones. In addition, the Bright Action Plan for the Prevention and Control of Myopia in Children and Adolescents (2021-2025) emphasizes early detection and intervention for children’s eye health, indicating a growing focus on myopia prevention and treatment.

With strong policy support, China’s ophthalmology market, especially private specialist hospitals and chains, is experiencing rapid development, with private hospital chains growing by 20% annually. Factors such as aging populations, remote work, online learning, and increased screen time are contributing to the rising incidence of eye diseases. Public awareness of eye health is growing, creating a surge in demand for ophthalmic care.

As the ophthalmology industry expands at a pace faster than the overall healthcare sector, it has attracted increasing capital investment. In 2021, domestic financing exceeded RMB 8 billion, with the rapid development of private ophthalmology chains. For companies seeking to efficiently enter and expand in the Chinese market, partnering with an experienced commercial solutions provider is crucial.

HTDK traces its origins back to the century-old Swiss company DKSH, which established its China branch years ago. In recent years, HTDK has achieved rapid growth with the support of its shareholder, Warburg Pincus. Today, HTDK is China’s leading commercial solutions provider, specializing in high-value medical devices. The company offers end-to-end professional commercialization services, enhancing the accessibility of innovative global medical devices in China.

With a wealth of experience in cross-border business, HTDK has established long-term partnerships with numerous clients, covering multiple specialties such as ophthalmology, in vitro diagnostics, orthopedics, cardiology, neurology, and respiratory care. HTDK’s clients include globally recognized brands such as Alcon, MicroVention, Illumina, Smith & Nephew, Roche, Abbott, and Procter & Gamble.

Since beginning its commercialization services in ophthalmology in 2006, HTDK has accumulated extensive experience in building private chain partnerships, helping products quickly gain market traction, establishing nationwide distribution networks, and implementing efficient processes and information services.

Given the high demand for imported ophthalmic products, traditional high-cost, multi-stakeholder distribution models are no longer viable. The industry urgently requires end-to-end commercialization services, and HTDK’s unique strength lies in its ability to provide such solutions. These include product registration, import/export, warehousing, distribution, channel management, inventory control, and after-sales support, all within a nationwide distribution network.

In addition, HTDK offers a fully digitalized platform for business process management. The platform is built around SAP and enables intelligent, visible, and predictive operations. It integrates processes such as customs declaration, product coding and tracking, cross-border procurement, and warehousing, connecting upstream and downstream stakeholders through seamless information exchange.

Key Capabilities:

• Comprehensive Digital Platform: HTDK’s platform integrates the entire business process, from import/export to inventory and order management. The system is connected to customs, regulatory platforms, and tax systems, ensuring smooth and efficient information flow across the supply chain.
• Distribution Management: HTDK manages over 500 distributors across all provinces and cities in China, covering over 1,700 public hospitals, nearly 900 private hospitals, and 10,000 pharmacies. The company’s distribution network seamlessly integrates upstream and downstream operations, helping medical brands quickly enter and expand in China.

HTDK’s commercial services for the ophthalmology sector include two standout offerings: VMI (Vendor-Managed Inventory) virtual warehouses and direct supply services to private hospitals. The VMI system, powered by a localized management team and an intelligent platform, addresses issues such as timely invoicing, inventory security, and product expiration management. It facilitates the rapid commercialization of new products while enhancing clients’ cash flow and channel partnerships. Additionally, HTDK’s direct supply service provides comprehensive support to private hospitals, linking manufacturers’ strategies with hospital group needs.

The Future of HTDK in China’s Eye Health Industry

HTDK remains committed to working with global high-value medical device companies to drive the high-quality development of China’s healthcare market. By empowering the commercialization of ophthalmology products, HTDK aims to increase the market share of top products, reduce distribution costs, and expand the accessibility of innovative global healthcare technologies.